Medacta Group SA Logo

Medacta Group SA

0A05.L

(0.0)
Stock Price

113,20 CHF

7.35% ROA

10.27% ROE

55.45x PER

Market Cap.

2.617.058.947,04 CHF

61.2% DER

0.42% Yield

8.56% NPM

Medacta Group SA Stock Analysis

Medacta Group SA Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Medacta Group SA Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Medacta Group SA Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Medacta Group SA Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Hold

Medacta Group SA Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Medacta Group SA Revenue
Year Revenue Growth
2016 219.051.000
2017 244.683.000 10.48%
2018 272.610.000 10.24%
2019 310.623.000 12.24%
2020 302.492.000 -2.69%
2021 363.126.000 16.7%
2022 437.122.000 16.93%
2023 1.022.548.000 57.25%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Medacta Group SA Research and Development Expenses
Year Research and Development Expenses Growth
2016 3.110.000
2017 3.476.000 10.53%
2018 3.933.000 11.62%
2019 7.641.000 48.53%
2020 6.829.000 -11.89%
2021 11.306.000 39.6%
2022 16.222.999 30.31%
2023 42.912.000 62.19%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Medacta Group SA General and Administrative Expenses
Year General and Administrative Expenses Growth
2016 10.529.000
2017 9.444.000 -11.49%
2018 9.671.000 2.35%
2019 49.284.000 80.38%
2020 45.212.000 -9.01%
2021 49.831.000 9.27%
2022 60.621.000 17.8%
2023 127.324.000 52.39%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Medacta Group SA EBITDA
Year EBITDA Growth
2016 69.237.000
2017 71.572.000 3.26%
2018 85.540.000 16.33%
2019 66.498.000 -28.64%
2020 81.956.000 18.86%
2021 97.815.000 16.21%
2022 106.957.000 8.55%
2023 192.896.000 44.55%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Medacta Group SA Gross Profit
Year Gross Profit Growth
2016 164.551.000
2017 182.603.000 9.89%
2018 203.980.000 10.48%
2019 223.697.000 8.81%
2020 214.256.000 -4.41%
2021 261.247.000 17.99%
2022 305.256.000 14.42%
2023 687.924.000 55.63%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Medacta Group SA Net Profit
Year Net Profit Growth
2016 39.219.000
2017 33.496.000 -17.09%
2018 45.753.000 26.79%
2019 11.859.000 -285.81%
2020 37.091.000 68.03%
2021 51.521.000 28.01%
2022 46.249.000 -11.4%
2023 72.876.000 36.54%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Medacta Group SA Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2016 2
2017 2 0%
2018 2 50%
2019 1 0%
2020 2 100%
2021 3 50%
2022 2 0%
2023 4 33.33%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Medacta Group SA Free Cashflow
Year Free Cashflow Growth
2016 28.020.000
2017 11.474.000 -144.2%
2018 11.275.000 -1.76%
2019 1.161.000 -871.15%
2020 32.307.000 96.41%
2021 7.570.000 -326.78%
2022 10.352.000 26.87%
2023 5.428.001 -90.71%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Medacta Group SA Operating Cashflow
Year Operating Cashflow Growth
2016 56.313.000
2017 51.586.000 -9.16%
2018 66.408.000 22.32%
2019 42.635.000 -55.76%
2020 59.592.000 28.46%
2021 54.061.000 -10.23%
2022 73.510.000 26.46%
2023 37.661.000 -95.19%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Medacta Group SA Capital Expenditure
Year Capital Expenditure Growth
2016 28.293.000
2017 40.112.000 29.46%
2018 55.133.000 27.25%
2019 41.474.000 -32.93%
2020 27.285.000 -52%
2021 46.491.000 41.31%
2022 63.158.000 26.39%
2023 32.232.999 -95.94%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Medacta Group SA Equity
Year Equity Growth
2015 108.549.000
2016 146.872.000 26.09%
2017 101.670.000 -44.46%
2018 89.070.000 -14.15%
2019 123.234.000 27.72%
2020 164.717.000 25.18%
2021 226.397.000 27.24%
2022 274.655.000 17.57%
2023 330.038.000 16.78%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Medacta Group SA Assets
Year Assets Growth
2015 218.840.000
2016 269.682.000 18.85%
2017 299.810.000 10.05%
2018 365.596.000 17.99%
2019 412.564.000 11.38%
2020 441.935.000 6.65%
2021 489.266.000 9.67%
2022 584.488.000 16.29%
2023 695.871.000 16.01%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Medacta Group SA Liabilities
Year Liabilities Growth
2015 110.291.000
2016 122.810.000 10.19%
2017 198.140.000 38.02%
2018 276.526.000 28.35%
2019 289.330.000 4.43%
2020 277.218.000 -4.37%
2021 262.869.000 -5.46%
2022 309.833.000 15.16%
2023 365.833.000 15.31%

Medacta Group SA Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
25.51
Net Income per Share
2.37
Price to Earning Ratio
55.45x
Price To Sales Ratio
5.12x
POCF Ratio
34.96
PFCF Ratio
478.35
Price to Book Ratio
7.96
EV to Sales
5.48
EV Over EBITDA
23.39
EV to Operating CashFlow
37.25
EV to FreeCashFlow
511.47
Earnings Yield
0.02
FreeCashFlow Yield
0
Market Cap
2,62 Bil.
Enterprise Value
2,80 Bil.
Graham Number
29.62
Graham NetNet
-8.35

Income Statement Metrics

Net Income per Share
2.37
Income Quality
1.59
ROE
0.15
Return On Assets
0.05
Return On Capital Employed
0.1
Net Income per EBT
0.81
EBT Per Ebit
0.74
Ebit per Revenue
0.14
Effective Tax Rate
0.19

Margins

Sales, General, & Administrative to Revenue
0.13
Research & Developement to Revenue
0.04
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.68
Operating Profit Margin
0.14
Pretax Profit Margin
0.11
Net Profit Margin
0.09

Dividends

Dividend Yield
0
Dividend Yield %
0.42
Payout Ratio
0.23
Dividend Per Share
0.55

Operating Metrics

Operating Cashflow per Share
3.75
Free CashFlow per Share
0.27
Capex to Operating CashFlow
0.93
Capex to Revenue
0.14
Capex to Depreciation
1.4
Return on Invested Capital
0.12
Return on Tangible Assets
0.07
Days Sales Outstanding
67.64
Days Payables Outstanding
87.03
Days of Inventory on Hand
479.24
Receivables Turnover
5.4
Payables Turnover
4.19
Inventory Turnover
0.76
Capex per Share
3.48

Balance Sheet

Cash per Share
1,04
Book Value per Share
16,49
Tangible Book Value per Share
13.92
Shareholders Equity per Share
16.49
Interest Debt per Share
10.09
Debt to Equity
0.61
Debt to Assets
0.29
Net Debt to EBITDA
1.51
Current Ratio
2.33
Tangible Asset Value
0,28 Bil.
Net Current Asset Value
-0,02 Bil.
Invested Capital
517802000
Working Capital
0,20 Bil.
Intangibles to Total Assets
0.07
Average Receivables
0,09 Bil.
Average Payables
0,04 Bil.
Average Inventory
200202500
Debt to Market Cap
0.08

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Medacta Group SA Dividends
Year Dividends Growth
2023 1
2024 1 0%

Medacta Group SA Profile

About Medacta Group SA

Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Europe, North America, the Asia-Pacific, and internationally. It offers personalized kinematic models and 3D planning tools for use in hip, knee, shoulder, sports medicine, and spine procedures. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.

CEO
Dr. Francesco Siccardi
Employee
1.826
Address
Strada Regina, 34
Castel San Pietro, 6874

Medacta Group SA Executives & BODs

Medacta Group SA Executives & BODs
# Name Age
1 Mr. Alessandro Siccardi
Chief Supply Chain Officer
70
2 Dr. Francesco Siccardi
Chief Executive Officer
70
3 Mr. Massimiliano Bernardoni
Chief Innovation Officer
70
4 Mr. Asif Hussain
Chief People Officer
70
5 Donato Cortesi
Secretary of the Board
70
6 Filippo Cappelli
Head of IT
70
7 Dr. Alberto Siccardi
Founder & Non Executive Chairman
70
8 Mr. Corrado Farsetta
Chief Financial Officer
70
9 Gianluca Olgiati
Senior Director of Global Marketing
70
10 Mr. Giovanni Niccolo Galli
Chief Commercial Officer
70

Medacta Group SA Competitors